Welcome to our dedicated page for BOSTON SCIENTIFIC SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BOSTON SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BOSTON SCIENTIFIC's regulatory disclosures and financial reporting.
Boston Scientific Corporation approved a new global restructuring program, the 2026 Restructuring Plan, on July 21, 2026. The plan is intended to drive sustained cost efficiencies and support growth by optimizing the supply chain, transferring certain production lines among facilities, and reshaping functional and organizational structures.
The program is expected to be initiated in 2026 and substantially completed by the end of 2029. Boston Scientific estimates total pre-tax charges of $700 million to $800 million, including $300 million to $350 million of transfer costs, $275 million to $300 million of termination benefits, and $125 million to $150 million of other costs such as consulting, contractual cancellations, program management, accelerated depreciation and fixed asset write-offs. Of the total charges, $600 million to $700 million are expected to result in future cash outlays.
The company expects the plan to reduce gross annual pre-tax expenses by approximately $500 million as benefits are realized, with a substantial portion of these savings to be reinvested in strategic growth initiatives. While new roles will be created in growth areas, the company does expect some headcount reductions as a result of the restructuring.
Boston Scientific EVP and CFO Jonathan Monson reported routine equity compensation activity involving restricted stock units. He exercised 2,087 restricted stock units into 2,087 shares of common stock and, in a related tax-withholding disposition, 1,010 shares were withheld at a price of $43.06 per share to cover tax obligations. After these transactions, he directly holds 39,063 shares of common stock and 6,263 restricted stock units, which each represent a commitment by the company to issue one share of common stock in the future, with shares to be issued in four equal annual installments beginning on July 1, 2026.
Boston Scientific Chairman, President & CEO Michael F. Mahoney reported a large charitable-style transfer of stock. He made a bona fide gift of 386,755 shares of Boston Scientific common stock on May 28, 2026 to The Michael F. Mahoney Term Irrevocable Trust - 2026, which is administered by an independent trustee.
After this transaction, Mahoney continues to hold 1,403,784 shares of Boston Scientific common stock directly. The gift is a non-market disposition with no sale proceeds reported, meaning it does not reflect open-market buying or selling activity in the stock.
Boston Scientific director Cheryl Pegus bought 1,770 shares of common stock in an open-market transaction. The purchase occurred at a weighted average price of about $56.49 per share, across multiple trades priced between $56.49 and $56.5009. After this transaction, she directly owns 1,770 shares.
BOSTON SCIENTIFIC CORP director Edward J. Ludwig made an open-market purchase of 3,580 shares of Common Stock at $56.68 per share. The transaction occurred on May 20, 2026 and increased his direct ownership to 25,359 shares following the trade.
Boston Scientific Corp director David C. Habiger reported buying additional company stock in two recent open-market transactions. He purchased 2,200 shares of Common Stock on May 19, 2026 at a weighted average price of $56.9451 per share, and 2,250 shares on May 20, 2026 at a weighted average price of $55.9195 per share. According to the filing, individual trades on each day occurred within narrow price ranges around these averages. Following these purchases, Habiger directly owns 13,878 Boston Scientific common shares.
Boston Scientific Corporation has entered into a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank as part of its previously announced $5 billion share repurchase authorization. The company will initially receive shares equal to 80% of the repurchase price, or about 30.4 million shares, based on the May 15, 2026 closing price of $52.68 per share. The final number of shares will be set using the volume‑weighted average price of the stock during the ASR term, less a discount, with settlement expected by June 30, 2026. After this transaction, $3 billion will remain available under the authorization, and management expects the ASR to add $0.02 to adjusted earnings per share for full‑year 2026 versus prior guidance.
Boston Scientific Corporation has made a major strategic investment in MiRus LLC, a private developer of cardiovascular and orthopedic technologies, including the SIEGEL transcatheter aortic valve replacement (TAVR) system. The company paid $1.5 billion in cash for non-voting equity and an exclusive option on the TAVR business.
The investment gives Boston Scientific 33.75% of MiRus on a fully diluted basis and a Call Option to acquire 100% of a new MiRus subsidiary holding the TAVR assets for additional aggregate cash payments totaling $3.0 billion, contingent on clinical and regulatory milestones. MiRus may also receive future sales-based payments if the option is exercised.
The SIEGEL TAVR valve uses a proprietary nickel-free rhenium alloy, dry porcine tissue leaflets and an 8 French delivery system designed to reduce vascular complications. MiRus has begun the STAR pivotal trial in up to 1,025 severe aortic stenosis patients. Boston Scientific expects the MiRus investment to be immaterial to its adjusted earnings per share in 2026.
Zane Ellen M reported acquisition or exercise transactions in this Form 4 filing.
BOSTON SCIENTIFIC CORP director Ellen M. Zane received an annual equity award of common stock. She was granted 3,800 shares of restricted stock on May 7, 2026 at no cash cost per share. The award reflects a value of $215,000 divided by the closing price of the common stock on the grant date and will vest in full at the next annual meeting of stockholders. After this grant, she directly holds 27,934 common shares.
WICHMANN DAVID S reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director David S. Wichmann received an annual equity award of 3,800 shares of Common Stock on May 7, 2026. The grant was made at no cash cost to him and is structured as restricted stock that vests in full at the next annual stockholders’ meeting.
After this award, he directly owns 45,382 shares. The filing notes the grant reflects a value of $215,000, calculated by dividing that amount by the closing price of Boston Scientific’s common stock on the grant date.